Risk factors for cyclosporin A nephrotoxicity in children with steroid-dependant nephrotic syndrome

Severin Kengne-Wafo, Laura Massella, Francesca Diomedi-Camassei, Alessandra Gianviti, Marina Vivarelli, Marcella Greco, Gilda Rita Stringini, Francesco Emma

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Background and objectives: Cyclosporin A (CsA) is a well-established treatment for steroid-dependent nephrotic syndrome (SDNS) that may, however, cause chronic ischemic renal lesions. The objective of the study was to assess the prevalence of CsA nephrotoxicity (CsAN) in protocol biopsies of children with SDNS. Design, settings, participants, & measurements: From 1990 through 2008, we performed 71 renal biopsies in 53 patients with SDNS. The mean CsA C2 levels were 466 ± 134 ng/ml, and the mean duration of treatment was 4.7 ± 2.0 yr before biopsy (range 2.9 to 12.7 yr). Results: CsAN was observed in 22 (31%) of 71 renal biopsies. Of these, 11 corresponded to isolated vascular or tubular lesions, and 11 corresponded to combined vascular and tubular lesions. The majority of CsAN lesions were mild (17 of 22). In no cases were lesions graded as severe. By regression analysis, CsAN was positively associated with the use of angiotensinconverting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) and with hyperuricemia and negatively associated with minimal-change lesions. By multivariate analysis, only association with the use of ACEIs or ARBs retained significance. Stratification of the population according to CsA C2 levels showed increased risk for CsAN for C2 levels >600 ng/ml. Conclusions: Mild to moderate CsAN occurs in approximately one third of patients who have SDNS and are treated with CsA for >3 yr. Our data suggest that patients who require high dosages of CsA or treatment for hypertension, in particular when ACEIs/ARBs are used, are at higher risk for CsAN.

Original languageEnglish
Pages (from-to)1409-1416
Number of pages8
JournalClinical Journal of the American Society of Nephrology
Volume4
Issue number9
DOIs
Publication statusPublished - 2009

Fingerprint

Nephrotic Syndrome
Cyclosporine
Steroids
Angiotensin Receptor Antagonists
Enzyme Inhibitors
Biopsy
Kidney
Blood Vessels
Hyperuricemia
Therapeutics
Multivariate Analysis
Regression Analysis
Hypertension
Population

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine
  • Epidemiology
  • Nephrology
  • Transplantation

Cite this

Risk factors for cyclosporin A nephrotoxicity in children with steroid-dependant nephrotic syndrome. / Kengne-Wafo, Severin; Massella, Laura; Diomedi-Camassei, Francesca; Gianviti, Alessandra; Vivarelli, Marina; Greco, Marcella; Stringini, Gilda Rita; Emma, Francesco.

In: Clinical Journal of the American Society of Nephrology, Vol. 4, No. 9, 2009, p. 1409-1416.

Research output: Contribution to journalArticle

Kengne-Wafo, Severin ; Massella, Laura ; Diomedi-Camassei, Francesca ; Gianviti, Alessandra ; Vivarelli, Marina ; Greco, Marcella ; Stringini, Gilda Rita ; Emma, Francesco. / Risk factors for cyclosporin A nephrotoxicity in children with steroid-dependant nephrotic syndrome. In: Clinical Journal of the American Society of Nephrology. 2009 ; Vol. 4, No. 9. pp. 1409-1416.
@article{a6ae6fbdb12d4737b92449cbb88e3697,
title = "Risk factors for cyclosporin A nephrotoxicity in children with steroid-dependant nephrotic syndrome",
abstract = "Background and objectives: Cyclosporin A (CsA) is a well-established treatment for steroid-dependent nephrotic syndrome (SDNS) that may, however, cause chronic ischemic renal lesions. The objective of the study was to assess the prevalence of CsA nephrotoxicity (CsAN) in protocol biopsies of children with SDNS. Design, settings, participants, & measurements: From 1990 through 2008, we performed 71 renal biopsies in 53 patients with SDNS. The mean CsA C2 levels were 466 ± 134 ng/ml, and the mean duration of treatment was 4.7 ± 2.0 yr before biopsy (range 2.9 to 12.7 yr). Results: CsAN was observed in 22 (31{\%}) of 71 renal biopsies. Of these, 11 corresponded to isolated vascular or tubular lesions, and 11 corresponded to combined vascular and tubular lesions. The majority of CsAN lesions were mild (17 of 22). In no cases were lesions graded as severe. By regression analysis, CsAN was positively associated with the use of angiotensinconverting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) and with hyperuricemia and negatively associated with minimal-change lesions. By multivariate analysis, only association with the use of ACEIs or ARBs retained significance. Stratification of the population according to CsA C2 levels showed increased risk for CsAN for C2 levels >600 ng/ml. Conclusions: Mild to moderate CsAN occurs in approximately one third of patients who have SDNS and are treated with CsA for >3 yr. Our data suggest that patients who require high dosages of CsA or treatment for hypertension, in particular when ACEIs/ARBs are used, are at higher risk for CsAN.",
author = "Severin Kengne-Wafo and Laura Massella and Francesca Diomedi-Camassei and Alessandra Gianviti and Marina Vivarelli and Marcella Greco and Stringini, {Gilda Rita} and Francesco Emma",
year = "2009",
doi = "10.2215/CJN.01520209",
language = "English",
volume = "4",
pages = "1409--1416",
journal = "Clinical journal of the American Society of Nephrology : CJASN",
issn = "1555-9041",
publisher = "by the American Society of Nephrology",
number = "9",

}

TY - JOUR

T1 - Risk factors for cyclosporin A nephrotoxicity in children with steroid-dependant nephrotic syndrome

AU - Kengne-Wafo, Severin

AU - Massella, Laura

AU - Diomedi-Camassei, Francesca

AU - Gianviti, Alessandra

AU - Vivarelli, Marina

AU - Greco, Marcella

AU - Stringini, Gilda Rita

AU - Emma, Francesco

PY - 2009

Y1 - 2009

N2 - Background and objectives: Cyclosporin A (CsA) is a well-established treatment for steroid-dependent nephrotic syndrome (SDNS) that may, however, cause chronic ischemic renal lesions. The objective of the study was to assess the prevalence of CsA nephrotoxicity (CsAN) in protocol biopsies of children with SDNS. Design, settings, participants, & measurements: From 1990 through 2008, we performed 71 renal biopsies in 53 patients with SDNS. The mean CsA C2 levels were 466 ± 134 ng/ml, and the mean duration of treatment was 4.7 ± 2.0 yr before biopsy (range 2.9 to 12.7 yr). Results: CsAN was observed in 22 (31%) of 71 renal biopsies. Of these, 11 corresponded to isolated vascular or tubular lesions, and 11 corresponded to combined vascular and tubular lesions. The majority of CsAN lesions were mild (17 of 22). In no cases were lesions graded as severe. By regression analysis, CsAN was positively associated with the use of angiotensinconverting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) and with hyperuricemia and negatively associated with minimal-change lesions. By multivariate analysis, only association with the use of ACEIs or ARBs retained significance. Stratification of the population according to CsA C2 levels showed increased risk for CsAN for C2 levels >600 ng/ml. Conclusions: Mild to moderate CsAN occurs in approximately one third of patients who have SDNS and are treated with CsA for >3 yr. Our data suggest that patients who require high dosages of CsA or treatment for hypertension, in particular when ACEIs/ARBs are used, are at higher risk for CsAN.

AB - Background and objectives: Cyclosporin A (CsA) is a well-established treatment for steroid-dependent nephrotic syndrome (SDNS) that may, however, cause chronic ischemic renal lesions. The objective of the study was to assess the prevalence of CsA nephrotoxicity (CsAN) in protocol biopsies of children with SDNS. Design, settings, participants, & measurements: From 1990 through 2008, we performed 71 renal biopsies in 53 patients with SDNS. The mean CsA C2 levels were 466 ± 134 ng/ml, and the mean duration of treatment was 4.7 ± 2.0 yr before biopsy (range 2.9 to 12.7 yr). Results: CsAN was observed in 22 (31%) of 71 renal biopsies. Of these, 11 corresponded to isolated vascular or tubular lesions, and 11 corresponded to combined vascular and tubular lesions. The majority of CsAN lesions were mild (17 of 22). In no cases were lesions graded as severe. By regression analysis, CsAN was positively associated with the use of angiotensinconverting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) and with hyperuricemia and negatively associated with minimal-change lesions. By multivariate analysis, only association with the use of ACEIs or ARBs retained significance. Stratification of the population according to CsA C2 levels showed increased risk for CsAN for C2 levels >600 ng/ml. Conclusions: Mild to moderate CsAN occurs in approximately one third of patients who have SDNS and are treated with CsA for >3 yr. Our data suggest that patients who require high dosages of CsA or treatment for hypertension, in particular when ACEIs/ARBs are used, are at higher risk for CsAN.

UR - http://www.scopus.com/inward/record.url?scp=73249130184&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73249130184&partnerID=8YFLogxK

U2 - 10.2215/CJN.01520209

DO - 10.2215/CJN.01520209

M3 - Article

C2 - 19628686

AN - SCOPUS:73249130184

VL - 4

SP - 1409

EP - 1416

JO - Clinical journal of the American Society of Nephrology : CJASN

JF - Clinical journal of the American Society of Nephrology : CJASN

SN - 1555-9041

IS - 9

ER -